IFF Q2 2026: Portfolio Restructuring and Regulatory Costs Overshadow Solid Operations
IFF sits 37% above its 52-week low of $59.14.
Summary
IFF's Q2 2026 results deliver 2% sales growth and strong cash flow, but the quarter is defined by the strategic reclassification of its Food Ingredients business as discontinued operations and a $27 million loss on the CitraSource sale. A new $2.5 billion buyback authorization signals confidence, while regulatory costs and a high tax rate pressured earnings.
Key Events · Earnings and Guidance · IFF
-
Q2 2026 Financial Results
Net sales reached $1.954 billion, up 2% on a reported basis and 6% in comparable currency-neutral terms. Net income came in at $51 million, or $0.20 per diluted share. Operating cash flow for the first half of 2026 nearly doubled the prior-year period, hitting $679 million.
-
Food Ingredients Classified as Discontinued Operations
The planned $4.3 billion sale of the Food Ingredients business to CVC Capital Partners met the criteria for held-for-sale and discontinued operations. Results are now reported separately, with the transaction expected to close by mid-2027.
-
CitraSource Held-for-Sale Loss
A $27 million pre-tax loss was recorded to write down the CitraSource business to its fair value less costs to sell of $41 million. The sale closed on July 1, 2026.
-
Regulatory and Tax Headwinds
Regulatory costs of $71 million related to fragrance industry investigations, combined with a high effective tax rate of 48.4%, significantly reduced net income from continuing operations.
Analysis · IFF · Industrial Applications And Services
A solid operational quarter featuring 2% sales growth and robust cash flow takes a back seat to IFF's strategic pivot: the Food Ingredients business moves to discontinued operations, and a $27 million loss is booked on the CitraSource held-for-sale classification. Regulatory costs of $71 million and an elevated 48.4% effective tax rate further compressed net income. Looking ahead, the $2.5 billion share repurchase authorization signals confidence in the post-divestiture future, yet the expected $200–300 million loss on the Botanical Extracts sale injects near-term uncertainty. The quarter captures a company in transition—shedding assets to concentrate on higher-margin Taste, Health & Biosciences, and Scent segments while managing legacy legal and regulatory headwinds.
At the time of this filing, IFF was trading at $81.00 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $20.7B. The 52-week trading range was $59.14 to $84.45. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.